SeaStar Medical at H.C. Wainwright: adult trial looms over small cap

On 11 September 2026 at the H.C. Wainwright 28th Annual Global Investment Conference, SeaStar Medical CEO Eric Schlorff presented a dual narrative about the company's two product pipelines - a pediatric therapy QUELIMMUNE, already on the market, and an adult acute kidney injury (AKI) program NEUTRALIZE-AKI, still in development.

The stock closed at $3.03, down 3.19% from the day before, and further declined to $2.98 in after-hours trading, reflecting the volatility typical of small biotech companies with market caps around $15 million.

QUELIMMUNE, a device-based therapy targeting hyperinflammation in children with acute kidney injury, showed 77% survival at 60 days in clinical trials, compared to a 50% survival rate in historical controls. SeaStar is on track to reach about 25 customers by year-end 2026, with about 20 customers as of the last earnings report. The pediatric market is small, with about 4,000 cases annually in the U.S. and $100 million in annual revenue, while the adult market is vastly larger, with about 200,000 cases annually and $4.5 billion in annual revenue.

The company is preparing to launch NEUTRALIZE-AKI, an adult trial of the same therapy, with more than 65% enrollment and completion expected by year-end 2026 or early 2027. A CMS billing code for inpatient use is set to take effect on 1 October 2026, potentially enabling faster reimbursement for adult use. SeaStar has received various designations from the FDA and has a Premarket Approval (PMA) filing planned for 2027 for NEUTRALIZE-AKI.

The company's main value driver is the NEUTRALIZE-AKI study, a randomized controlled trial of 339 patients, with an expected completion by year-end 2026 or early 2027.